ReviewCurrent topics in medicinal chemistry2026
A Review on the Development of Semisynthetic Phytochemicals in the Discovery of Anticancer Drugs.
Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a serious public health problem worldwide, and research into the development of new targeted cancer drugs is continuing intensively. A wide variety of approaches have been developed, ranging from traditional cytotoxic agents to modern targeted therapies, antibody-drug conjugates, immunotherapies, and advanced drug delivery systems, etc. The integration of omics strategies, bioinformatics, network pharmacology, molecular docking, molecular dynamics simulation, and artificial intelligence techniques into the process has accelerated the development of modern cancer treatments. While the search for different cancer treatment methods and anticancer drugs continues intensively, semi-synthetic drug designs still attract attention. As most targeted anticancer drugs are insufficient in clinical treatment, natural products and their derivatives are important in new multi-targeted anticancer drug research. Alongside traditional plant-derived anticancer agents, cardamonin, harmin, podophyllotoxin, β-carboline, magnolol, α-onocerin, boehmeriasin A, parthenolide, celastrol, pinosembrin, furochromone, curcumin, diosgenin, betulinic acid, ursolic acid, honokiol, goniodiol, scopoletin, caffeic acid, and pinocembrin derivatives have attracted interest due to their enhanced efficacy and selectivity relative to their natural analogs. These phytochemicals or their derivatives offer new strategies and have the potential to reduce the side effects of traditional treatments and overcome drug resistance. This review aims to discuss recent semisynthetic advancements in natural product research for anticancer drug development. It demonstrates that several semisynthetic anticancer candidates with enhanced selective anticancer effects compared to natural precursors have been developed, and that problems such as low bioactivity, poor solubility, or selectivity issues can be effectively resolved through the rational design of the chemical structures of their natural analogs.
Indexed as
Identifiers
41968693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.